Leonard Mermel, DO

Warren Alpert Medical School of Brown University and Rhode Island Hospital

Disclosure(s): Citius Pharma: Advisor/Consultant; CorMedix Pharma: Advisor/Consultant; Destiny Pharma: Board Member; Lightline Medical: Advisor/Consultant; Pristine Access Technology: Advisor/Consultant, Stocks/Bonds (Private Company)

Poster(s):

• (P-17) Outcomes of Patients with Suspected Central Venous Catheter-Related Bloodstream Infections Receiving Antimicrobial Lock Therapy for Catheter Salvage
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-101) A Phase 3 International, Multi-Center, Randomized, Open-Label, Assessor-Blind Study to Evaluate the Efficacy and Safety of Minocycline/EDTA/Ethanol (Mino-Lok) Therapy (MLT) vs Site-Specific Antimicrobial Lock in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET